The Iroko pipeline is a reflection of Iroko’s mission to develop and commercialize innovative treatment options for responsible pain management. Iroko is actively pursuing new products and technologies that help meet this goal.

About Iroko’s pipeline

  • Iroko’s pipeline includes three low-dose SoluMatrix® NSAIDs in various stages of nonclinical and clinical development
  • The safety and efficacy of these investigational products are being evaluated for management of osteoarthritis pain and mild to moderate acute pain
Therapeutic Target
Compound Name
Nonclinical
Phase I
Phase II
Phase III
NDA/sNDA
Osteoarthritis Pain
SoluMatrix® Naproxen
Phase II
Acute Pain & Osteoarthritis Pain
IP NCB
Nonclinical
Acute Pain & Osteoarthritis Pain
IP NIB
Nonclinical